Home / Market News / $INO
fiscal.ai Corporate Catalyst Impact 95/100 ● positive

Inovio Receives FDA Accelerated Approval for VOCERYQ to Treat Recurrent Respiratory Papillomatosis

Oct 31, 2026, 1:09 PM UTC · Primary ticker $INO

Inovio Pharmaceuticals announced FDA accelerated approval for VOCERYQ, a plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis. This marks a significant milestone as the first such approval in the US, validating Inovio's technology and paving the way for commercialization, with product availability in 60 days and full launch by Q1 2027.

Inovio Pharmaceuticals received FDA accelerated approval for VOCERYQ, its plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis. This is a major positive catalyst for the company, as it represents the first FDA approval for a plasmid DNA-based immunotherapy in the US, validating their proprietary CELLECTRA delivery platform and opening a new market. The short-term implication is a boost in investor confidence and potential for revenue generation within 60 days, with a full commercial launch anticipated in Q1 2027. The long-term opportunity lies in establishing a foothold in the RRP market and leveraging this approval for future pipeline candidates. A key risk is the requirement for a post-marketing confirmatory study, which could impact the drug's long-term status if results are not favorable.

$INO positive FDA accelerated approval of key product
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.